This Drug Could End H.I.V. Why Hasn’t It?

The Daily

• Episode: This Drug Could End H.I.V. Why Hasn’t It?
• Website: The Daily
• Feed URL: http://rss.art19.com/the-daily
• Duration: 00:27:17
• Published: 2019-06-05 11:52

Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily.

Background reading:

• Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but critics questioned the company’s motives.
• The high cost of drugs remains a major obstacle to ending the AIDS epidemic.
• Here’s more information about PrEP from the Centers for Disease Control and Prevention website.